scholarly journals New Drug Sotorasib Reduces Tumor Size and Promises to Improve and Increase Survival in Patients with Lung Tumors Caused by Specific DNA Mutations

2021 ◽  
pp. 462-502
Author(s):  
Ricardo Gobato ◽  
Abhijit Mitra
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
The United States ◽  
Lung Tumors ◽  
Small Cell ◽  
Small Cell Lung ◽  
New Drug ◽  
Dna Mutations

According to the results of a global phase 2 clinical trial, the new drug stores reduce tumor size and promises to improve and increase survival in patients with lung tumors caused by specific DNA mutations. It is designed to counteract the effects of mutations that are seen in about 13% of patients with non-small cell lung adenocarcinoma (a common type of lung cancer). The Food and Drug Administration (FDA) on May 28 approved the drug as a targeted treatment for patients with small cell lung cancer whose tumors express a specific mutation called G12C in the KRAS gene. Small cell lung cancer accounts for more than 80% of lung cancers. More than 200,000 new cases of non-small cell lung cancer are diagnosed in the United States each year. Keywords: Cancer; Cells; Tissues; Tumors; Prevention; Prognosis; Diagnosis; Imaging; Screening, Treatment; Management

scholarly journals Significant Role of Nanoparticles as a Drug Delivery System for Cancer Treatment

2021 ◽  
pp. 383-423
Author(s):  
Alireza Heidari ◽  
Ricardo Gobato ◽  
Abhijit Mitra
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Dna Mutations ◽  
Phase 2 Clinical Trial ◽  
Keywords Cancer

According to the results of a global phase 2 clinical trial, the new drug sotorasib reduces tumor size and promises to improve and increase survival in patients with lung tumors caused by specific DNA mutations. It is designed to counteract the effects of mutations that are seen in about 13% of patients with non-small cell lung adenocarcinoma (a common type of lung cancer). The Food and Drug Administration (FDA) on May 28 approved the drug as a targeted treatment for patients with small cell lung cancer whose tumors express a specific mutation called G12C in the KRAS gene. Small cell lung cancer accounts for more than 80% of lung cancers. More than 200,000 new cases of non-small cell lung cancer are diagnosed in the United States each year. Keywords: Cancer; Cells; Tissues; Tumors; Prevention; Prognosis; Diagnosis; Imaging; Screening, Treatment; Management

scholarly journals Progress and Challenges of Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer

2021 ◽  
pp. 395-433
Author(s):  
Elena Locci ◽  
Silvia Raymond
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Dna Mutations ◽  
Phase 2 Clinical Trial ◽  
Keywords Cancer

According to the results of a global phase 2 clinical trial, the new drug sotorasib reduces tumor size and promises to improve and increase survival in patients with lung tumors caused by specific DNA mutations. It is designed to counteract the effects of mutations that are seen in about 13% of patients with non-small cell lung adenocarcinoma (a common type of lung cancer). The Food and Drug Administration (FDA) on May 28 approved the drug as a targeted treatment for patients with small cell lung cancer whose tumors express a specific mutation called G12C in the KRAS gene. Small cell lung cancer accounts for more than 80% of lung cancers. More than 200,000 new cases of non-small cell lung cancer are diagnosed in the United States each year. Keywords: Cancer; Cells; Tissues, Tumors; Prevention, Prognosis; Diagnosis; Imaging; Screening; Treatment; Management

New drug and multimodality combinations in the treatment of advanced non[ndash ]small cell lung cancer

2001 ◽  
Vol 28 (3 Suppl 9) ◽  
pp. 1-4
Author(s):  
Masaaki Kawahara ◽  
Mark G. Kris ◽  
Mark Green ◽  
Hideo Kunitoh
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
New Drug

scholarly journals Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study

2018 ◽  
Vol Volume 11 ◽  
pp. 4573-4582 ◽  
Author(s):  
Martin Reck ◽  
Anders Mellemgaard ◽  
Silvia Novello ◽  
Pieter E Postmus ◽  
Birgit Gaschler-Markefski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Cancer Tumor

Corrigendum to “Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter” [Lung Cancer 46 (2004) 325–331]

Lung Cancer ◽  
2005 ◽  
Vol 50 (2) ◽  
pp. 281-282
Author(s):  
Ayten Kayi Cangir ◽  
Hakan Kutlay ◽  
Murat Akal ◽  
Adem Güngör ◽  
Nezih Özdemir ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Prognostic Value ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Changes of Tumor Size and Tumor Contrast Enhancement during Radiotherapy for Non-small-cell Lung Cancer May Be Suggestive of Treatment Response

2012 ◽  
Vol 53 (2) ◽  
pp. 326-332 ◽  
Author(s):  
Hiroshi OKADA ◽  
Shigeto HONTSU ◽  
Sachiko MIURA ◽  
Isao ASAKAWA ◽  
Tetsuro TAMAMOTO ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Contrast Enhancement ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Small Cell ◽  
Small Cell Lung

Tumor Size Predicts Survival Within Stage IA Non-Small Cell Lung Cancer *

CHEST Journal ◽  
2003 ◽  
Vol 124 (5) ◽  
pp. 1828-1833 ◽  
Author(s):  
Jeffrey L. Port ◽  
Michael S. Kent ◽  
Robert J. Korst ◽  
Daniel Libby ◽  
Mark Pasmantier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ia
Sign in / Sign up

Export Citation Format

Share Document